Cyolo Security Announces Partnership with TD SYNNEX
Cyolo, the access company for the industrial enterprise, today announced a new partnership with TD SYNNEX, a leading global distributor and solutions aggregator for the IT ecosystem. The powerful combination of TD SYNNEX’s solution aggregation capabilities and Cyolo’s highly disruptive, distributed secure remote access platform will lead partners to new service lines of revenue. The partnership empowers TD SYNNEX and Cyolo partners to tap into the increased enterprise demand of Secure Remote Access in operational technology (OT), critical infrastructure, cyber physical environments, and their corresponding buying centers.
The partnership with TD SYNNEX serves as the cornerstone of the Cyolo PRO (Privilege Remote Operations) launch. The recently launched Cyolo PRO Platform allows service providers, integrators, OT, IT personnel and other third parties to securely access and safely operate applications, devices and systems in the most critical environments. Cyolo PRO takes secure remote access to new levels with its distributed architecture and its converged security stack capabilities. Cyolo is cloud routed and cloud managed without being cloud hosted. Unlike current technologies such as VPN and SASE that provide users with full access to the network, Cyolo PRO enables secure and privileged access by connecting robustly verified identities to applications with persistent authorization.
“The strategic nature of our TD SYNNEX relationship is a pivotal step in realizing our commitment to delivering future-ready, safe and secure privilege access solutions to the massive industrial market,” said Cyolo’s EVP Corporate Development and OT GM Joe O’Donnell. “Through this collaboration, TD SYNNEX’s partners can bring Cyolo PRO to a broader range of OT, IT and Cyber Physical stakeholders. This increases safety, security and accelerates operational agility. The solution’s capability to seamlessly fit into existing architectures without extensive change management processes is critical in OT environments, as even the slightest network and security change can yield significant consequences.”
This global partnership enables thousands of TD SYNNEX integrators, VARs, MSSPs and Carriers to provide next generation SRA/RPAM (Remote Privilege Access Management) services to their respective customers. Cyolo PRO enables TD SYNNEX partners to address the fast-growing OT and Cyber Physical markets by focusing on crucial elements that increase their clients’ operational agility, improves customers’ security and providing safe yet swift implementations with the lowest cost of change.
"TD SYNNEX is committed to uniting IT solutions that deliver business outcomes today and unlock growth for the future," said Cheryl Day, VP Vendor Acquisition and Global Solutions at TD SYNNEX. "With Cyolo added to our vast portfolio of vendor partners, we're able to enrich the breadth and depth of our offerings so customers can do great things with technology."
To learn more about Cyolo PRO, please visit: https://cyolo.io/product
About Cyolo
Cyolo replaces current SRA implementations with next gen privileged remote operations by connecting verified identities directly to applications with continuous authorization throughout the connection. Purpose-built for deployment in every type of environment, Cyolo PRO combines multiple Remote Privilege Access Management (RPAM) security functions required to mitigate high-risk access, including zero-trust access for users and devices, MFA for the last mile, IdP capabilities, credentials vault, secure file transfer, supervised access, session recording, and much more into a single, cost-effective, easy-to-deploy, and user-friendly platform. For more information visit cyolo.io or follow us on LinkedIn and X.
About TD SYNNEX
TD SYNNEX (NYSE: SNX) is a leading global distributor and solutions aggregator for the IT ecosystem. We’re an innovative partner helping more than 150,000 customers in 100+ countries to maximize the value of technology investments, demonstrate business outcomes and unlock growth opportunities. Headquartered in Clearwater, Florida, and Fremont, California, TD SYNNEX’s 23,000 co-workers are dedicated to uniting compelling IT products, services and solutions from 2,500+ best-in-class technology vendors. Our edge-to-cloud portfolio is anchored in some of the highest-growth technology segments including cloud, cybersecurity, big data/analytics, AI, IoT, mobility and everything as a service. TD SYNNEX is committed to serving customers and communities, and we believe we can have a positive impact on our people and our planet, intentionally acting as a respected corporate citizen. We aspire to be a diverse and inclusive employer of choice for talent across the IT ecosystem. For more information, visit www.TDSYNNEX.com, follow our newsroom or follow us on LinkedIn, Facebook and Instagram.
Copyright 2024 TD SYNNEX Corporation. All rights reserved. TD SYNNEX, the TD SYNNEX Logo, and all other TD SYNNEX company, product and services names and slogans are trademarks of TD SYNNEX Corporation. Other names and trademarks are the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240326860005/en/
Contact information
Cyolo Media Inquiries
10Fold
cyolo@10Fold.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom